Author:
Romero Klaus,Sinha Vikram,Allerheiligen Sandra,Danhof Meindert,Pinheiro Jose,Kruhlak Naomi,Wang Yaning,Wang Sue-Jane,Sauer John-Michael,Marier J. F.,Corrigan Brian,Rogers James,Lambers Heerspink H. J.,Gumbo Tawanda,Vis Peter,Watkins Paul,Morrison Tina,Gillespie William,Gordon Mark Forrest,Stephenson Diane,Hanna Debra,Pfister Marc,Lalonde Richard,Colatsky Thomas
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products, Accessed online 26 Feb 2013: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm
2. Kruhlak NL, Benz RD, Zhou H, Colatsky TJ (2012) (Q)SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther 91:529–534
3. Wang SJ, Hung HM (2013) Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations. Contemp Clin Trials 36:673–681
4. Avalide drug label, updated in 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020758s064lbl.pdf
5. Food and Drug Administration (2010) Guidance for Industry: qualification process for drug development tools. Accessed online 3 Apr 2013 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献